Cantor Fitzgerald Estimates Sanara MedTech FY2025 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Sanara MedTech in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings per share of ($1.09) for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $44.00 target price on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.33) per share.

Separately, HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Sanara MedTech in a report on Thursday.

Sanara MedTech Price Performance

Shares of NASDAQ SMTI traded up $0.40 during midday trading on Thursday, reaching $38.12. 32,994 shares of the company were exchanged, compared to its average volume of 32,692. The stock's 50-day moving average price is $34.66 and its 200-day moving average price is $32.84. The stock has a market cap of $333.17 million, a P/E ratio of -38.51 and a beta of 1.55. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76. Sanara MedTech has a one year low of $26.00 and a one year high of $40.75.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.28. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. The firm had revenue of $21.67 million during the quarter. During the same period in the previous year, the firm posted ($0.13) EPS.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SMTI. State Street Corp grew its holdings in Sanara MedTech by 9.2% during the 3rd quarter. State Street Corp now owns 58,688 shares of the company's stock worth $1,775,000 after acquiring an additional 4,932 shares during the last quarter. Barclays PLC grew its stake in shares of Sanara MedTech by 323.0% in the third quarter. Barclays PLC now owns 5,731 shares of the company's stock worth $174,000 after purchasing an additional 4,376 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Sanara MedTech by 4.4% in the third quarter. Geode Capital Management LLC now owns 88,271 shares of the company's stock worth $2,670,000 after purchasing an additional 3,755 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Sanara MedTech by 127.2% in the third quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company's stock valued at $123,000 after purchasing an additional 2,272 shares during the period. Finally, Fifth Third Bancorp bought a new position in Sanara MedTech during the 4th quarter worth $898,000. Institutional investors own 8.10% of the company's stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.